Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma


Disclosures: Shaji Kumar has been a non-paid consultant or advisory board member for AbbVie, Celgene, Janssen, Kite Pharma, Merck, and Takeda and is the Principal Investigator in clinical trials supported by Bristol-Myers Squibb, Celgene, Janssen, Kite Pharma, Roche/Genentech, Sanofi, and Takeda. The other authors report no conflicts of interest.